zelicapavir (EDP-938) (RSVP)

October 13, 2026: Enanta Pharmaceuticals (NASDAQ: ENTA) announced that zelicapavir, an oral once-daily N-protein inhibitor for respiratory syncytial virus (RSV), will be presented at IDWeek 2026 (October 21-24, 2026).

The presentation is a poster titled “Zelicapavir Decreases Time to Complete RSV Symptom Resolution, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of High-Risk Adults,” indicating Phase 2 data in high-risk adults with RSV. The poster suggests improvements versus placebo in time to complete symptom resolution, hospitalization, and viral load.

Presentation details: Poster Session “Novel Agents,” Poster No. 3, on Thursday, October 22, 2026, from 12:15 PM to 1:30 PM ET in Poster Hall B-C, presented by Christopher E. Harris, M.D. The poster will also be available on the conference platform and the company’s website during the meeting.